Clinical perspectives and treatment preferences for sertaconazole in the management of cutaneous fungal infections

Manjula S.; Krishna Kumar M.

doi:10.18203/issn.2455-4529.IntJResDermatol20254122

Authors

Manjula S. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India
Krishna Kumar M. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20254122

Keywords:

Sertaconazole, Fungal infections, Dermatophytosis, Tinea pedis, Tinea corporis, Topical antifungals

Abstract

Background: Despite several clinical studies regarding the effectiveness of sertaconazole in various cutaneous fungal infections, there is a dearth of studies among clinicians. So, this study aims to assess clinician preferences and perceived efficacy of sertaconazole in the management of fungal infections across multiple dermatological indications.

Methods: This cross-sectional study enrolled 599 dermatologists, and data were collected using a structured 23-item questionnaire regarding clinical characteristics, diagnostic approaches, treatment preferences, and perceived efficacy for topical antifungals, with a specific focus on sertaconazole usage. Descriptive statistics were employed for data analysis.

Results: Out of 599 dermatologists, the majority (52.85%) preferred sertaconazole as the topical azole of choice for tinea pedis, while nearly 61% preferred it for tinea corporis. Clinical efficacy was rated as “very good” by approximately 42% of respondents, and 51% attributed sertaconazole’s superiority to its dual fungistatic and fungicidal activity. Occasional use was reported in pityriasis versicolor (72.56%) and seborrheic dermatitis (68.09%). About 62% of clinicians cited good efficacy as the key advantage, while 39% highlighted a combination of efficacy, tolerability, and sustained effect. The cream formulation was preferred by about 87% of participants.

Conclusions: Sertaconazole is strongly preferred by clinicians for managing fungal infections in dermatology, particularly tinea pedis and tinea corporis, owing to its dual fungistatic and fungicidal activity, high perceived efficacy, and tolerability. Its expanding use in pityriasis versicolor and seborrheic dermatitis indicates growing recognition of its broader therapeutic potential.

Metrics

Metrics Loading ...

References

Ameen M. Epidemiology of superficial fungal infections. Clin Dermatol. 2010;28(2):197–201. DOI: https://doi.org/10.1016/j.clindermatol.2009.12.005

Howell SA. Dermatopathology and the Diagnosis of Fungal Infections. Br J Biomed Sci. 2023;80:11314. DOI: https://doi.org/10.3389/bjbs.2023.11314

Li D, Fan S, Zhao H, Song J, Guo L, Li W, et al. Worldwide trends and future projections of fungal skin disease burden: a comprehensive analysis from the Global Burden of Diseases study 2021. Front Public Health. 2025;13:1580221. DOI: https://doi.org/10.3389/fpubh.2025.1580221

Bhargava S, Chakrabarty S, T Damodaran R, Kumar Saikia P, Shenoy M, Bangale N, et al. Rising burden of superficial fungal infections in India and the role of Clotrimazole for optimal management. IP Indian J Clin Exp Dermatol. 2025;9(1):1–16. DOI: https://doi.org/10.18231/j.ijced.2023.001

Urban K, Chu S, Scheufele C, Giesey RL, Mehrmal S, Uppal P, et al. The global, regional, and national burden of fungal skin diseases in 195 countries and territories: A cross-sectional analysis from the Global Burden of Disease Study 2017. JAAD Int. 2020;2:22–7. DOI: https://doi.org/10.1016/j.jdin.2020.10.003

Jamil RA, Saxena K, Koti VR, Mohanty S. A Dermatophytosis- its impact on quality of life and financial burden: Research Article. Int J Med Biomed Studies. 2023;7(1):07–13. DOI: https://doi.org/10.32553/ijmbs.v7i1.2640

Kruithoff C, Gamal A, McCormick TS, Ghannoum MA. Dermatophyte Infections Worldwide: Increase in Incidence and Associated Antifungal Resistance. Life (Basel). 2023;14(1):1. DOI: https://doi.org/10.3390/life14010001

Choudhary S, Bisati S, Singh A, Koley S. Efficacy and Safety of Terbinafine Hydrochloride 1% Cream vs. Sertaconazole Nitrate 2% Cream in Tinea Corporis and Tinea Cruris: A Comparative Therapeutic Trial. Indian J Dermatol. 2013;58(6):457–60. DOI: https://doi.org/10.4103/0019-5154.119958

Del Rosso JQ. Comprehensive management of patients with superficial fungal infections: the role of sertaconazole nitrate. Cutis. 2008;81(6 Suppl):4–18.

Borelli C, Klövekorn G, Ernst TM, Bödeker RH, Korting HC, Neumeister C. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis. Am J Clin Dermatol. 2007;8(6):371–8. DOI: https://doi.org/10.2165/00128071-200708060-00007

Borelli C, Korting HC, Bödeker RH, Neumeister C. Safety and efficacy of sertaconazole nitrate cream 2% in the treatment of tinea pedis interdigitalis: a subgroup analysis. Cutis. 2010;85(2):107–11.

Tatavarthi LNB, Ramachandra B, Rao DS, Srinivasulu G. Clinical evaluation of efficacy of sertaconazole 2% cream in treatment of pityriasis versicolor and a comparison with that of clotrimazole 1% cream. J Evol Med Dent Sci. 2015;4(27):4668-75. DOI: https://doi.org/10.14260/jemds/2015/675

Kothari R, Sadoughifar R, Lotti T, Goldust M. Efficacy of 1% clotrimazole cream versus 2% sertaconazole cream in the management of seborrheic dermatitis: A randomized controlled trial. Russian J Skin Venereal Dis. 2020;23(3):146–9. DOI: https://doi.org/10.17816/dv48905

Goldust M, Rezaee E, Masoudnia S, Raghifar R. Clinical study of sertaconazole 2% cream vs. hydrocortisone 1% cream in the treatment of seborrheic dermatitis. Ann Parasitol. 2013;59(3):119-23.

Carrillo-Muñoz AJ, Tur-Tur C, Cárdenes DC, Estivill D, Giusiano G. Sertaconazole Nitrate Shows Fungicidal and Fungistatic Activities against Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, Causative Agents of Tinea Pedis▿. Antimicrob Agents Chemother. 2011;55(9):4420–1. DOI: https://doi.org/10.1128/AAC.00219-11

Carrillo-Muñoz AJ, Giusiano G, Ezkurra PA, Quindós G. Sertaconazole: updated review of a topical antifungal agent. Expert Rev Anti Infect Ther. 2005;3(3):333–42. DOI: https://doi.org/10.1586/14787210.3.3.333

Weinberg JM, Koestenblatt EK. Treatment of interdigital tinea pedis: once-daily therapy with sertaconazole nitrate. J Drugs Dermatol. 2011;10(10):1135–40.

Sharma A, Saple DG, Surjushe A, Rao GRR, Kura M, Ghosh S, et al. Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. Mycoses. 2011;54(3):217–22. DOI: https://doi.org/10.1111/j.1439-0507.2009.01801.x

Goldust M, Rezaee E, Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. Ann Parasitol. 2013;59(1):25–9. DOI: https://doi.org/10.3109/09546634.2012.755251

Chatterjee D, Ghosh SK, Sen S, Sarkar S, Hazra A, De R. Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study. Indian J Pharmacol. 2016;48(6):659–64. DOI: https://doi.org/10.4103/0253-7613.194850

Georgescu SR, Mitran CI, Mitran MI, Amuzescu A, Matei C, Tampa M. A Meta-Analysis on the Effectiveness of Sertaconazole 2% Cream Compared with Other Topical Therapies for Seborrheic Dermatitis. J Pers Med. 2022;12(9):1540. DOI: https://doi.org/10.3390/jpm12091540